

SANOFI-AVENTIS  
Form 6-K  
May 30, 2007  
UNITED STATES

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2007

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form	Form
20-F <input checked="" type="checkbox"/>	40-F <input type="checkbox"/>

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

---

## Edgar Filing: SANOFI-AVENTIS - Form 6-K

In May 2007, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are incorporated herein by reference.

### Exhibit List

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated May 18, 2007 regarding the approval of Lovenox® for use in the treatment of the most severe type of heart attack.
Exhibit 99.2	Press release dated May 25, 2007 regarding data to be presented at the ASCO annual meeting.
Exhibit 99.3	Press release dated May 29, 2007 regarding U.S. approval of XYZAL®

Edgar Filing: SANOFI-AVENTIS - Form 6-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 30, 2007

SANOFI-AVENTIS

By: /s/ Patricia Kodyra

Name: Patricia Kodyra

Title: Associate Vice President

Financial and Securities Law

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated May 18, 2007 regarding the approval of Lovenox® for use in the treatment of the most severe type of heart attack.
Exhibit 99.2	Press release dated May 25, 2007 regarding data to be presented at the ASCO annual meeting.
Exhibit 99.3	Press release dated May 29, 2007 regarding U.S. approval of XYZAL®